Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Available only through CTSU Registration
This is a multicenter study. Patients are stratified according to age (≤ 70 years vs. > 70 years), race (African American vs. other), and time of baseline prostate biopsy (0-12 months before registration vs. > 12-24 months before registration). Patients are randomized to 1 of 2 treatment arms.
Patients receive the MEAL program intervention with dietary education and telephone counseling sessions for 24 months. Patients receive the "Participant Notebook", which provides written material describing the counseling program. It also outlines the dietary targets, offers supporting information on strategies to achieve these targets, supplies referent tools to help patients accurately estimate servings of target foods, and offers recipes and articles about diet and prostate cancer. The counseling sessions are divided into 4 phases, with the first three phases completed in 7 months and the fourth phase continuing for 17 months. The first phase comprises 6 counseling calls focusing on education and the rapid development of self-efficacy, the second phase comprises 4 calls over a 2-month period focusing on practical and consistent implementation of the dietary pattern, the third phase comprises 4 calls over a 4-month period helping patients habituate to the dietary pattern by providing regular performance reviews, and the fourth phase comprises 8 calls over a 17-month period and is a maintenance phase. Patients are encouraged to achieve 7 servings per day of vegetables (2 cruciferous, 2 tomato products, 3 other vegetables), 2 servings per day of whole grains, 1 serving per day of beans or other legumes, and 2 servings per day of fruit. Patients also receive 8 regularly scheduled newsletters over the course of 24 months. The newsletters focus on study goals and progress and provide tips on achieving and maintaining diet change. They also include information on diet and cancer, the challenges of diet change, the advances in prostate cancer control, and new recipes.
Patients receive standard United States Department of Agriculture dietary guidelines for Americans. Patients also receive 8 regularly scheduled newsletters over the course of 24 months. The newsletters contain general information about diet and healthy lifestyle.
Blood (plasma and serum) and tissue samples are collected at baseline and at 12 and 24 months for biomarker and pharmacogenomic studies. Patients complete quality-of-life assessments (Personal Habits Questionnaire, Functional Assessment of Cancer Therapy Scale-Prostate (FACT-P), Memorial Anxiety Scare for Prostate Cancer (Max-PC), International Prostate Symptom Score (IPSS), Expanded Prostate Cancer Index Composite 26 (EPIC-26), and Nutrition Self-Efficacy and Satisfaction with the MEAL Program) at baseline and at 6, 12, 18, and 24 months. After study entry, patients are followed up every 3 months for 2 years.
the fourth phase comprises 8 calls over a 17-month period and is a maintenance phase.
Progression defined by PSA doubling time (PSADT) < 3 years, PSA > 10 at any time, or Gleason sum on repeat biopsy ≥ 7 (for men < 70 years) or ≥ 4+3 = 7 (for men ≥ 70 year)
National Enrollment to Date: 284/464
Available only through CTSU Registration
This is a multicenter study.
Patients are stratified according to pathologic stage (intermediate high-risk vs. very high-risk), histologic subtype (clear cell vs. non-clear cell), and performance status (0 vs. 1). Patients are randomized to 1 of 2 treatment arms.
-Archived tumor tissue, plasma, and whole blood samples may be collected periodically for biomarker analysis and other translational studies.
-After completion of study treatment, patients are followed up every 6 months for 2 years and then annually for 8 years.
Ambulatory, early stage (I or II) breast and prostate cancer survivors who are at least two years out of treatment (excluding hormonal therapy) with no severe co-morbid DISEASE
PRIOR CONCURRENT THERAPY:
National Enrollment to Date: 592/1170